Free Trial
NASDAQ:IMMX

Immix Biopharma Q4 2024 Earnings Report

Immix Biopharma logo
$2.10 +0.06 (+2.94%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.10 0.00 (-0.24%)
As of 05/2/2025 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immix Biopharma EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Immix Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immix Biopharma Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Immix Biopharma's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Immix Biopharma Earnings Headlines

Donald Trump is about to free crypto from its chains …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
See More Immix Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immix Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immix Biopharma and other key companies, straight to your email.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

View Immix Biopharma Profile

More Earnings Resources from MarketBeat